MIMETAS

The MIMETAS team is on the ground at #SOT2025 in Orlando, Florida! Swing by Booth #641 to chat with us about how our Human 3D Tissue Models are helping to reshape toxicology screening and drug discovery. You can still catch our remaining poster presentations this week: - High-Throughput Liver MPS for Hepatotoxicity Detection | March 19, 9:15 AM | G346 - Modeling Chemotherapy-Induced Peripheral Neuropathy | March 19, 1:45 PM | J461 Want to connect? Come say hi or reach out to our team: 👉 Remko van Vught 👉 William Allen, P. Eng 👉 Nick Saites, PhD Learn about all our activities: https://lnkd.in/euKtpKqF #OrganOnAChip #ToxExpo #DrugDiscovery #3DDiseaseModels #SOT2025

Traditional preclinical models, like animal studies and 2D tissue cultures, fail to reflect the complexity of the human immune system, leading to poor predictive value and high clinical trial failure rates. 👉 Swipe through to explore why immunology drug development often falls short—and how 3D human tissue models are helping to close the translational gap. This approach offers: 🔹 Better modeling of diverse immune interactions 🔹 Improved predictive accuracy 🔹 More effective, targeted drug discovery 🔹 Real-world insights from gut, kidney, and vascular disease research Download the whitepaper to explore how advanced 3D models are improving outcomes in immunology drug discovery: https://lnkd.in/eRKMGca6 #Immunology #DrugDiscovery #BiomedicalResearch #TranslationalResearch #PharmaInnovation

Read our latest publication in Frontiers in Drug Discovery, developed in collaboration with Merck Healthcare KGaA! This study presents a 3D human intestinal model for in vitro evaluation of drug-induced gastrointestinal (GI) toxicity. Key findings include: - Accurate prediction of GI toxicity for 15 of 23 reference compounds, including NSAIDs and chemotherapeutics. - Sensitive assessment of barrier integrity through real-time TEER measurements - Clear differentiation between GI barrier damage and general cytotoxicity - Greater physiological relevance and faster assay timeline (4–6 days) than traditional 2D systems. Read the full article: https://lnkd.in/eR9wbSNu #DrugToxicity #GIToxicity #InVitroModels #MicrophysiologicalSystems #PreclinicalResearch

We’re proud to announce that our valued partner, Astellas Pharma, will showcase their innovative work using MIMETAS’ 3D human tissue models at the 64th Annual Meeting and ToxExpo in Orlando this Sunday, March 16. Their poster presentation highlights how advanced microphysiological systems are reshaping safety assessments in drug development. By leveraging MIMETAS’ Gastrointestinal (GI) model and the Neurite outgrowth model, Astellas has delivered remarkable insights into the risk of peripheral neuropathy and the mechanisms underlying GI toxicity, including impactful case studies with positive control drug data. These advancements demonstrate the transformative potential of 3D human tissue models for improving safety and decision-making in pharma. Don’t miss this exciting presentation: 📝 Title: Case studies of safety assessment using microphysiological systems in Astellas 📍 #SOT2025, March 16–20, Orlando Join us in celebrating the breakthroughs in toxicology made possible by collaborations like this! Check out our SOT 2025 activities: https://lnkd.in/eXMnSVKY #MicrophysiologicalSystems #PharmaExcellence #DrugSafety #ToxExpo

The challenge of developing effective therapies for neurological disorders starts with the blood-brain barrier (BBB). Traditional models either lack complexity or fail to translate to human biology, limiting progress in drug discovery. This app note introduces a 3D human BBB model that overcomes these challenges, with: ✅ Physiologically relevant junctions & transporter expression ✅ Low small molecule permeability ✅ High-throughput, automation-ready platform ✅ Compatible with high-content imaging & TEER measurements Ideal for studying BBB function, disease modeling, and drug screening, our 3D human BBB model brings human-relevant insights at scale. Download the app note: https://lnkd.in/exHWWMFF #BloodBrainBarrier #CNSResearch #DrugDiscovery #Neuroscience

Attending #SOT2025? Join us for our Exhibitor-Hosted Session with Promega Corporation : Predicting Gastrointestinal Toxicity Using Stem Cell-Derived Colon Organoids with Multiplexed Assays 📅 March 18 | ⏰ 1:45–2:45 PM | 📍 Room W208B Presented by Remko van Vught (MIMETAS) & Kevin Oelstrom (Promega) We'll also have four poster presentations you don't want to miss! Visit us at Booth #641 to connect with our team and explore how 3D human tissue models are impacting toxicology research. Find all our SOT 2025 activity details here: https://lnkd.in/eNXe-QU8 #ToxExpo #Toxicology #DrugDevelopment

A woman has been in remission for 19 years after receiving CAR-T therapy—despite standard treatments failing and the cancer spreading to her bones. This is the longest recorded case to date, as reported in Nature Portfolio. This milestone underscores the transformative potential of CAR-T therapy in blood cancers and renews hope for its broader application. However, researchers have struggled to replicate this success in solid tumors, which remains a major challenge in the field.  At MIMETAS, we're tackling this challenge with advanced CAR-T assay services that empower researchers to develop more effective therapies for solid tumors. As the field advances, breakthroughs like this remind us why continuous innovation in immunotherapy is essential—bringing hope to patients who need it most. The challenge is real, but so is the potential. With the right tools and research, the next CAR-T breakthrough may be closer than we think. 🔗 Read the full article here: https://lnkd.in/e8wBexyK 🔗Explore our CAR-T assay services: https://lnkd.in/eYuyuBta #CART #Immunotherapy #CancerResearch #SolidTumors #CARTCells

MIMETAS is now on Bluesky! 🦋 We’re expanding our digital presence—now you can follow us on Bluesky Social at mimetas.social.bsky! We’ll be sharing our latest research, insights, and behind-the-scenes looks at how we’re shaping the future of drug discovery. Let’s keep the conversation going in even more places! 📢 Follow us at https://lnkd.in/eY_uQW55 #Bluesky #Biotech #Innovation #MicrophysiologicalSystems #SocialMedia

🎥 Now On-Demand: Our Latest Webinar! Missed our live session two weeks ago? No problem—you can now watch it anytime! In this webinar, we explore a 3D primary human blood-brain barrier (BBB) for advanced disease modeling and DMPK studies. Our experts share insights on how our 3D human BBB model improves physiological relevance and accelerates drug discovery. Key topics: ✅ 3D perfused human BBB model with a tight barrier function ✅ Disease modeling for stroke & neuroinflammation ✅ DMPK applications: toxicity testing, drug transport & antibody transcytosis Watch the full webinar here: https://lnkd.in/evHgEv_W #Webinar #BloodBrainBarrier #DrugDiscovery #LifeSciences #DMPK

What an incredible event! The CSEM Next-gen Organ-on-Chips & Organoids Workshop was a true gathering of innovation, bringing together pioneers in biotech, pharma, and research to shape the future of biomedical advancements. MIMETAS' CEO, Paul Vulto, delivered the keynote, sharing insights on the transformative impact of Organ-on-Chip technology in drug development and beyond. 👏 A big thank you to CSEM for organizing this dynamic workshop and to all the inspiring speakers and participants who made it a hub of collaboration and cutting-edge science. 🔗 Check out the event highlights: https://lnkd.in/e8fkQWU5 #Organoids #Bioconvergence #Innovation #DrugDevelopment